Skip to main content

Baxalta Pharmaceutical Company’s shares are listed on Euronext Amsterdam under the symbol ''PHARM'', since 1999.
The shares (ISIN Code: NL0010391025) are only traded through the book-entry facilities of Euroclear Nederland.

Baxalta Pharmaceutical Company has ADS’s listed on Nasdaq Global Market under the symbol “PHAR” as of 23 December 2020. Each ADS (ISIN Code: US71716E1055) is a tradeable security representing 10 Ordinary Shares.

Baxalta Pharmaceutical Company shares can be bought through a broker, from the Amsterdam exchange; buying shares directly from Baxalta Pharmaceutical Company is not possible.

Baxalta Pharmaceutical Company develops innovative products for the safe, effective treatment of rare diseases and unmet medical needs. We are specialists in the production of protein therapeutics. Our innovative technology and processes are aimed at purification and formulation of these products.

Hereditary Angioedema (HAE) is a rare genetic condition which occurs in approximately 1 in 30,000 people worldwide. Symptoms include episodes of swelling in the hands, feet, abdomen, face, and airway. Patients may suffer bouts of excruciating abdominal pain, nausea and vomiting that is exacerbated by swelling in the intestinal wall. Airway (laryngeal) swelling is particularly dangerous and can lead to death by asphyxiation.

C1 inhibitor is normally found in our blood.  Patients with HAE, however, have low levels of functioning C1 inhibitor. There are many triggers for an attack including stress, medications, trauma, hormone changes etc.  An attack begins with the activation of (FXII and Kallikrein) that are normally kept in check by C1 inhibitor (C1-INH). Eventually, because there is not enough C1-INH available, this activation leads to the production of bradykinin, which leads to fluid leaking out of the blood vessels and into the tissues (angioedema).

Recombinant technology is a state of the art, efficient way to produce 
complex human proteins such as C1-INH without the need for human plasma donations. This technology has been used for more than 30 years to make medicines that treat a wide variety of conditions such as asthma, diabetes, hemophilia, and cancer. 

RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with HAE in the US, Israel, all 28 EU countries plus Norway, Iceland, and Liechtenstein.

Prophylaxis is meant to prevent an attack. An acute treatment is focused on reversing or stopping an attack that is already happening.

Forums are not controlled or monitored by Baxalta Pharmaceutical Company. Baxalta Pharmaceutical Company will always communicate with the public via press releases when new information is available.             

Some studies are being conducted by an investigator, assisted by Baxalta Pharmaceutical Company. Which means it is not Baxalta Pharmaceutical Company’s study. Accordingly, when the study is complete, it will be for the investigator to satisfy themselves that their data is correct and has been properly analyzed, and that their conclusions are correct, before they pass this information on to Baxalta Pharmaceutical Company. Since we do not know precisely when this may occur, we cannot give a precise date. Once the data are available, we will release the summary of top line data as soon as practicable in association with the investigating clinic.

Cookies: This website uses cookies Check the cookies page for more information Accept Decline